Your browser doesn't support javascript.
loading
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.
Yam, Clinton; Xu, Xiaowei; Davies, Michael A; Gimotty, Phyllis A; Morrissette, Jennifer J D; Tetzlaff, Michael T; Wani, Khalida M; Liu, Shujing; Deng, Wanleng; Buckley, Meghan; Zhao, Jianhua; Amaravadi, Ravi K; Haas, Naomi B; Kudchadkar, Ragini R; Pavlick, Anna C; Sosman, Jeffrey A; Tawbi, Hussein; Walker, Luke; Schuchter, Lynn M; Karakousis, Giorgos C; Gangadhar, Tara C.
Afiliação
  • Yam C; Abramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Xu X; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Davies MA; Abramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Gimotty PA; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Morrissette JJD; Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Tetzlaff MT; Center for Personalized Diagnostics, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Wani KM; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Liu S; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Deng W; Abramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Buckley M; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Zhao J; Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Amaravadi RK; Center for Personalized Diagnostics, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Haas NB; Abramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Kudchadkar RR; Abramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Pavlick AC; H. Lee Moffitt Cancer Center, Tampa, Florida.
  • Sosman JA; New York University Medical Center, New York, New York.
  • Tawbi H; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
  • Walker L; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Schuchter LM; The University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Karakousis GC; Cascadian Therapeutics (formerly Oncothyreon) Inc., Seattle, Washington.
  • Gangadhar TC; Abramson Cancer Center and the Division of Hematology & Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Clin Cancer Res ; 24(1): 22-32, 2018 01 01.
Article em En | MEDLINE | ID: mdl-29051322
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas B-raf / Inibidores de Fosfoinositídeo-3 Quinase / Mutação / Neoplasias Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas B-raf / Inibidores de Fosfoinositídeo-3 Quinase / Mutação / Neoplasias Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Ano de publicação: 2018 Tipo de documento: Article